[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Qingxia Li\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":45},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":5},"100603674","the-efficacy-and-safety-of-iparomlimabtuvonralimab-anti-pd-1ctla-4-combined-with-albumin-bound-paclitaxel-in-second-line-treatment-of-patients-with-advanced-gastricgastroesophageal-junction-adenocarcinoma-100603674",false,"NCT07139587","The Efficacy and Safety of Iparomlimab\u002FTuvonralimab (Anti PD-1\u002FCTLA-4) Combined With Albumin-bound Paclitaxel in Second-line Treatment of Patients With Advanced Gastric\u002FGastroesophageal Junction Adenocarcinoma","Inclusion Criteria:\n\n* Aged 18-75;\n* ECOG PS 0-2;\n* Histologically confirmed advanced of the gastric cancer\u002Fgastroesophageal junction adenocarcinoma;\n* Failure of first-line treatment: Progression or intolerance after receiving platinum-based (oxaliplatin\u002Fcisplatin) + fluorouracil (5-FU\u002F capecitabine \u002FS-1) regimens;\n* The first-line use of PD-1 inhibitors is permitted;\n* At least one measurable lesion (RECIST v1.1);\n* Good organ function (ANC≥1.5×109\u002FL, PLT≥100×109\u002FL, with normal liver and kidney functions）.\n\nExclusion Criteria:\n\n* Her2-positive gastric cancer\u002Fgastroesophageal junction adenocarcinoma;\n* Active autoimmune disease;\n* Previously received PD-1\u002FCTLA-4 bispecific antibody or taxanes at first-line treatment.","ALL","18 Years","75 Years",{"count":19,"type":20},30,"ESTIMATED","INTERVENTIONAL",[23],"NA","The goal of this clinical trial is to evaluate the efficacy and safety of Iparomlimab and Tuvonralimab (anti PD-1\u002FCTLA-4) combined with albumin-paclitaxel in the second-line treatment of patients with advanced gastric\u002Fgastroesophageal junction adenocarcinoma. The main questions it aims to answer are: 1. Can the combination of Iparomlimab\u002FTuvonralimab and albumin-paclitaxel for advanced gastric cancer\u002Fgastroesophageal junction cancer who has progressed or is intolerant to first-line SOC prolong the PFS and OS, improve ORR, DCR, and prolong DoR; 2. Whether Iparomlimab\u002FTuvonralimab ( anti PD-1\u002FCTLA-4) combined with albumin-paclitaxel for second-line treatment remains effective for patients who have progressed from first-line PD-1±chemotherapy; 3. The safety and tolerability of Iparomlimab\u002FTuvonralimab in combination with albumin-paclitaxel for second-line treatment.Participants will:1. Use Iparomlimab\u002FTuvonralimab 5.0mg\u002Fkg, D1, Q3W; At least 30 minutes later, administer the chemotherapy albumin-paclitaxel: 260mg\u002Fm², D1, Q3W, and complete the infusion within 30 minutes. The combined regimen was administered every 3 weeks, with efficacy evaluated every 2 cycles (RECIST 1.1) until disease progression, intolerable toxicity or patient withdrawal.",[26,27],"Gastric Cancer","Gastroesophageal Junction Adenocarcinoma",[29,30,31,32],"Immunotherapy","gastric cancer","gastroesophageal junction adenocarcinoma","PD-1\u002FCTLA-4","NOT_YET_RECRUITING","2025-09-08",{"date":36,"type":37},"2025-09-10","ACTUAL",{"date":39,"type":20},"2025-09",{"date":41,"type":20},"2028-12",{"name":43,"class":44},"Qingxia Li","OTHER",""]